Browsing: pharmaceuticals

Health Canada has approved IMCIVREE (setmelanotide) for weight management in patients as young as 4 with acquired hypothalamic obesity — the first targeted therapy approved in Canada for the rare condition.

CSL Canada says the first patients are now receiving ANDEMBRY, the first once-monthly treatment targeting factor XIIa for hereditary angioedema prevention — with public coverage expanding in Quebec, Alberta, and through federal programs.